Privia Health Group (NASDAQ:PRVA) Earns Overweight Rating from Analysts at Stephens

Privia Health Group, Inc.  logosStephens began coverage on shares of Privia Health Group (NASDAQ:PRVA – Get Rating) in a research note released on Tuesday morning, The Fly reports. The firm issued an overweight rating on the stock.

Other analysts also recently issued research reports about the company. BTIG Research lowered their target price on Privia Health Group from $45.00 to $40.00 in a research note on Monday, January 9th. Royal Bank of Canada assumed coverage on Privia Health Group in a report on Thursday, March 9th. They issued an outperform rating and a $36.00 target price for the company. Credit Suisse Group reaffirmed an outperform rating and set a $41.00 price objective on shares of Privia Health Group in a research note on Tuesday, March 7th. Finally, The Goldman Sachs Group initiated coverage on Privia Health Group in a report on Friday, February 3rd. They set a buy rating and a $32.00 price objective for the company. Fifteen analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $38.73.

Privia Health Group Stock Performance

Shares of PRVA stock opened at $28.06 on Tuesday. The stock has a 50 day moving average price of $27.39 and a two-hundred day moving average price of $27.32. The company has a market capitalization of $3.23 billion, a P/E ratio of -255.09, a PEG ratio of 3.82 and a beta of 0.77. Privia Health Group has a fifty-two week low of $17.99 and a fifty-two week high of $44.64.

Want More Great Investment Ideas?

Privia Health Group (NASDAQ:PRVA – Get Rating) last announced its earnings results on Tuesday, February 28th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.17. Privia Health Group had a negative return on equity of 0.25% and a negative net margin of 0.63%. The firm had revenue of $364.42 million during the quarter, compared to analysts’ expectations of $337.16 million. As a group, equity analysts predict that Privia Health Group will post 0.19 earnings per share for the current year.

Insider Transactions at Privia Health Group

In other Privia Health Group news, CFO David Mountcastle sold 5,506 shares of the stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $27.62, for a total transaction of $152,075.72. Following the completion of the transaction, the chief financial officer now directly owns 153,940 shares of the company’s stock, valued at approximately $4,251,822.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Privia Health Group news, COO Parth Mehrotra sold 53,560 shares of the firm’s stock in a transaction dated Tuesday, February 28th. The shares were sold at an average price of $28.13, for a total transaction of $1,506,642.80. Following the completion of the transaction, the chief operating officer now owns 97,391 shares in the company, valued at $2,739,608.83. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO David Mountcastle sold 5,506 shares of the firm’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $27.62, for a total transaction of $152,075.72. Following the completion of the sale, the chief financial officer now directly owns 153,940 shares of the company’s stock, valued at approximately $4,251,822.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 346,069 shares of company stock worth $9,583,555. 57.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Privia Health Group

A number of institutional investors and hedge funds have recently modified their holdings of PRVA. ProShare Advisors LLC acquired a new position in shares of Privia Health Group during the 1st quarter worth approximately $210,000. JPMorgan Chase & Co. increased its stake in Privia Health Group by 60.3% in the first quarter. JPMorgan Chase & Co. now owns 33,839 shares of the company’s stock valued at $905,000 after acquiring an additional 12,732 shares during the last quarter. US Bancorp DE increased its stake in Privia Health Group by 8.8% in the first quarter. US Bancorp DE now owns 13,923 shares of the company’s stock valued at $372,000 after acquiring an additional 1,131 shares during the last quarter. MetLife Investment Management LLC boosted its position in Privia Health Group by 200.9% in the first quarter. MetLife Investment Management LLC now owns 23,742 shares of the company’s stock valued at $635,000 after buying an additional 15,852 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Privia Health Group by 124.7% in the first quarter. Rhumbline Advisers now owns 36,873 shares of the company’s stock valued at $986,000 after buying an additional 20,464 shares in the last quarter. 66.83% of the stock is owned by institutional investors.

Privia Health Group Company Profile

(Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

Featured Stories

The Fly logo

Analyst Recommendations for Privia Health Group (NASDAQ:PRVA)

Receive News & Ratings for Privia Health Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Privia Health Group and related companies with MarketBeat.com’s FREE daily email newsletter.

Similar Posts